Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Systemic Treatments for the Management of Prurigo Nodularis : Episode 5

Opinion

Video

January 17, 2025

Practice Pearls for Managing Patients With Prurigo Nodularis

Author(s):

A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.

EP: 1.Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis

EP: 2.Advances in Systemic Treatment Options for Prurigo Nodularis

EP: 3.Managing Moderate Prurigo Nodularis in a 52-Year-Old Female With Atopic Dermatitis

EP: 4.Optimizing Severe Prurigo Nodularis Treatment in a 65-Year-Old Male With Multiple Comorbidities

Now Viewing

EP: 5.Practice Pearls for Managing Patients With Prurigo Nodularis

Video content above is prompted by the following:

Based on our discussion today, what key insights or new perspectives could you share regarding treatment considerations for systemic therapies for prurigo nodularis?
What take-home messages or practice pearls do you have for clinicians treating patients with prurigo nodularis?